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Abstract
Although nutrients, including amino acids and their metabolites such as serotonin (5-HT), are
strong modulators of anxiety-related behavior, the metabolic pathway(s) responsible for this
physiological modulation is not fully understood. Regarding tryptophan (Trp), the initial rate-
limiting enzymes for the kynurenine pathway of tryptophan metabolism are tryptophan 2,3-
dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO). Here, we generated mice deficient for
tdo (Tdo-/-). Compared with wild-type littermates, Tdo-/- mice showed increased plasma levels of Trp
and its metabolites 5-hydroxyindoleacetic acid (5-HIAA) and kynurenine, as well as increased levels
of Trp, 5-HT and 5-HIAA in the hippocampus and midbrain. These mice also showed anxiolytic
modulation in the elevated plus maze and open field tests, and increased adult neurogenesis, as
evidenced by double staining of BrdU and neural progenitor/neuronal markers. These findings
demonstrate a direct molecular link between Trp metabolism and neurogenesis and anxiety-related
behavior under physiological conditions.
Background
Mental disorders and affective status, in particular depres-
sion and anxiety disorders, are increasingly important
medical and social issues in the 21st century [1]. Although
associations with these conditions have been proposed
for a wide range of factors, including obesity, which may
play a role in them [2,3], the molecular mechanisms
remain to be precisely elucidated. Modulatory roles have
been proposed for various nutrients, including the amino
acid tryptophan (Trp) and its catabolite 5-hydroxytryp-
tamine (serotonin, 5-HT) [4,5], and also for several
enzymes in Trp metabolism. A loss-of-function mutation
(G1463A) in tryptophan hydroxylase-2 (TPH2), for exam-
ple, the rate-limiting enzyme in 5-HT synthesis ([6]; Fig-
ure 1A), has been identified as a factor in unipolar major
depression [7]. Further, antidepressants have been postu-
lated to act by directly inhibiting the activity of tryp-
tophan 2,3-dioxygenase (TDO/tryptophan pyrolase) [8-
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10], one of two rate-limiting enzymes for the kynurenine
pathway of Trp metabolism (Figure 1A), in turn enhanc-
ing the availability of cerebral Trp [11,12]. In several
genetic analyses, human TDO2 gene polymorphisms have
been potentially associated with psychiatric diseases, such
as Tourette syndrome, depression, and autism [13,14].
Conflicting results have also been reported [15], however,
and a direct molecular link between amino acid metabo-
lism and mental disorders/affective status has not been
well established.
Here, to better understand the metabolic pathways and
enzymes responsible for anxiety-related behavior, we gen-
erated Tdo knock-out (Tdo-/-) mice and assessed the role of
TDO in anxiety-related behavior and neurogenesis, and in
systemic and brain Trp metabolism.
Results
Generation of mice with targeted disruption of the tdo 
gene locus
We first disrupted the tdo gene in mice by homologous
recombination. The targeting vector was constructed by
replacing genomic tdo  exons 1 and 2 (containing the
translational initiation site) with the PGK-neomycin
(Neo) cassette (Figure 1B). Heterozygous mice were
crossed with C57BL/6 mice for five generations. Inter-
breeding of the resultant heterozygotes produced wild-
type (Tdo+/+), heterozygote (Tdo+/-), and homozygote
(Tdo-/-) mice, as identified by Southern blot analysis of
PvuII-digested genomic tail DNA (Figure 1C). The disrup-
tion of tdo was verified by the absence of tdo mRNA tran-
scripts and TDO protein in the liver, as assessed by
quantitative real-time PCR and Western blot analyses,
respectively (Figure 1D and 1E). The null mutation of tdo
was also verified by enzyme activity assays of liver extracts
(Figure 1F). These mutant mice were born at ratios that
followed Mendelian inheritance and matured for at least
one year without apparent gross abnormalities. As TDO is
predominantly expressed in the liver, we briefly looked at
gross liver morphology: although little difference between
13-week-old Tdo-/- and Tdo+/+ mice was seen, confirmation
of a lack of effect on the histological status of the liver will
require further detailed examination.
Marked increase in plasma Trp and altered plasma Trp 
metabolite levels in Tdo-/- adult mice
Since TDO is an early and rate-limiting enzyme for Trp
metabolism (Figure 1A) and may control systemic Trp
metabolism, we first examined the contribution of the tdo
null mutation to systemic levels of Trp and its metabo-
lites/catabolites. Results showed that Trp levels in plasma
were 9.3-fold higher in Tdo-/- than Tdo+/+ mice (Figure 2A
and additional file 1, Table S1). In contrast, no obvious
differences were seen in the levels of other essential amino
acids (EAAs), except for modest increases in threonine
(1.3-fold) and methionine (1.3-fold) (Figure 2B and addi-
tional file 1, Table S1). Measurement of the three Trp cat-
abolites in plasma by HPLC showed much higher levels of
5-HIAA, the catabolic product of Trp via the serotonin (5-
HT) pathway (Figure 1A(b)), in Tdo-/- than Tdo+/+ mice
(Figure 2C), as well as increases in indoleacetic acid (IAA)
and indolelactic acid (ILA) (Figure 2D and 2E), products
of Trp via the transamination pathway (Figure 1A(c)). In
contrast, no difference was seen in the plasma levels of Trp
between mice with knock-out of indoleamine 2,3-dioxygen-
ase (IDO) [16], one of the two enzymes that convert Trp
to formylkynurenine ([17,18]; Figure 1A), and wild-type
littermates (see additional file 1, Figure S1). These find-
ings clearly demonstrated that TDO is indeed largely
responsible for the systemic level of Trp, and that TDO
contributes to Trp catabolites (5-HIAA, ILA, and IAA) lev-
els in plasma, even in the presence of IDO.
We then examined whether levels of the major Trp metab-
olites kynurenine (Kyn) and kynurenic acid (KYNA) were
reduced by tdo deletion, on the basis that the marked ele-
vation of Trp in Tdo-/- mice suggested the insufficient com-
pensatory conversion of Trp to formylkynurenine by IDO.
Kyn levels were 2-fold higher in Tdo-/- than Tdo+/+ mice
(Figure 2F), whereas KYNA levels showed no significant
difference (Figure 2G).
Generation of tdo-deficient (Tdo-/-) mice Figure 1 (see previous page)
Generation of tdo-deficient (Tdo-/-) mice. (A) Schema of the Trp metabolic pathways. (a) the Kyn pathway. Over 95% of 
the dietary Trp is metabolized along this pathway. (b) the serotonin pathway. (c) the transamination pathway. (B) A targeting 
strategy for tdo gene disruption. Exons are represented as numbered boxes (coding regions; black boxes). The probe for South-
ern blot analysis is indicated by a solid bar. ApaI, A; PvuII, P; HindIII, H; EcoRI, E; XbaI, X; Neo, PGK-neomycin resistant cassette; 
DT-A, diphtheria toxin-A. (C) Southern blot analysis of representative progeny. Tail genomic DNA was digested with PvuII for 
hybridization with a specific probe against the intron sequence between exons 3 and 4 of tdo. The expected sizes of the hybrid-
ized DNA fragment for Tdo+/+ (+/+) and Tdo-/- (-/-) mice are 6.1 kb and 4.9 kb, respectively. (D) Quantitative real-time RT-PCR 
for tdo mRNA expression in adult liver. Mouse tdo/gapdh of adult liver in Tdo+/+ mice was arbitrarily given a value of 100%. Val-
ues are means ± S.D. (E) Western blot analysis. Total liver homogenates were immunoblotted with TDO-specific antiserum. 
(F) Assay for TDO enzyme activity, determined in total liver lysates from 10-week-old animals of each genotype. Values repre-
sent means ± S.D.Molecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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Effect of tdo deletion on systemic Trp metabolites Figure 2
Effect of tdo deletion on systemic Trp metabolites. (A-H) Plasma amino acid composition and Trp metabolites in 18- to 
20-week-old Tdo+/+ (+/+) and Tdo-/- (-/-) mice. Plasma Trp concentration (A), other essential amino acid (EAA-Trp) concentra-
tions (B), and the ratio of Trp to large neutral amino acids (LNAA, H) were determined using an amino acid analyzer (means ± 
S.E.). **, p < 0.0001. Plasma levels of 5-HIAA (C), IAA (D), ILA (E), kynurenine (Kyn: F), kynurenic acid (KYNA: G) were deter-
mined using HPLC-FD and HPLC-UV systems. Values represent means ± S.E. *, p < 0.05.Molecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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Enhanced brain 5-HT synthesis in adult Tdo-/- mice
Given that large neutral amino acids (LNAA) compete for
transport across the blood-brain barrier [2], the elevation
of Trp only among LNAA and consequent increase in the
Trp/LNAA ratio (Figure 2H) in Tdo-/- mice suggested the
increased transport of Trp across the blood-brain-barrier.
We therefore predicted that 5-HT synthesis in the brain
would be altered in Tdo-/- mice [19]. On HPLC analysis,
Trp concentrations in the hippocampus and midbrain
were more than 20-fold higher in Tdo-/- than Tdo+/+ mice
(Figure 3A and 3D), versus no obvious differences for the
other amino acids, except methionine (see additional file
1, Table S2). Levels of 5-HT in the midbrain (region of 5-
HT synthesis) and hippocampus (region of serotonergic
input) were also nearly 2-fold higher in Tdo-/- than Tdo+/+
mice (Figure 3E and 3B), and those of the 5-HT metabo-
lite 5-HIAA were nearly 5-fold higher (Figure 3C and 3F),
indicating the acceleration of 5-HT synthesis and turnover
in these mice. Given the notion that tryptophan hydroxy-
lase (TPH) is the rate-limiting enzyme for 5-HT biosynthe-
sis, we asked whether the level or activity of tph2 would be
modulated by TDO deletion. As shown in Figure 3G, how-
ever, mRNA level and enzymatic activity for TPH were not
modified in Tdo-/- mice, indicating that TDO, rather than
TPH, was the dominant regulator of 5-HT biosynthesis
under physiological conditions in vivo.
Modulation of anxiety-related behavior in 13- to 15-week-
old Tdo-/- mice
We next assessed whether TDO deletion modulated anxi-
ety-related behavior. There were a number of rationales
for this: changes in levels of Trp and its metabolite 5-HT
modulate either or both anxiety- and depression-related
behavior [20,21]; the important contribution proposed
for Trp and 5-HT dysregulation in many psychiatric disor-
ders, including anxiety, depression, schizophrenia, aggres-
sion, autism and alcoholism [20]; the possibility that
TDO is directly involved in several psychiatric conditions,
as evidenced by the potential association of human TDO2
gene polymorphisms with psychiatric diseases, such as
Tourette syndrome, depression, and autism [13,14]; and
the possibility that familial hypertryptophanemia, with its
associated mood abnormalities, is due to an inborn error
in the normal conversion of Trp to Kyn, albeit that the
causal gene for this disease has not yet been identified
[22]. Results showed that brain levels of Trp and 5-HT [2]
were markedly elevated in Tdo-/- mice (Figure 3).
To clarify the role of TDO deletion in anxiety-related
behavior, we next conducted two traditional anxiety-
behavior analyses in 13- to 15-week-old mice, the ele-
vated plus maze test (EPM) and the open field test (OFT).
In the EPM, Tdo-/- mice spent significantly longer times in
the open arms of the maze than Tdo+/+ mice (Figure 4A).
In contrast, no obvious differences were seen in locomo-
tor activity (Figure 4C) or time spent in the center zone
(Figure 4B). In the OFT, moreover, Tdo-/- mice showed
increased center locomotion (Figure 4D) and time spent
in the center zone (Figure 4E), but no difference in total
movement in the open field (Figure 4F). These results
clearly indicate that depletion of TDO induced anxiolytic
effects without affecting locomotor activity or the behav-
ioral phenotype of Tdo-/- mice.
Increased proliferation of neural progenitors in the 
dentate gyrus of the hippocampus in 13-week-old Tdo-/- 
mice
Given the previous finding that X-irradiation of a
restricted region of the mouse brain containing the hip-
pocampus inhibited the neurogenic and anxiety-related
behavioral effects of two classes of antidepressants, sug-
gesting that the behavioral effects of chronic antidepres-
sant use were mediated by the stimulation of
neurogenesis in the hippocampus [23], we next examined
whether neurogenesis is accelerated in the adult hippoc-
ampus of Tdo-/- mice. On H&E staining, hippocampus of
13-week-old  Tdo-/-  mice showed a greater number of
deeply stained cells with neurite-like spines in the sub-
granular zone (SGZ) and granular cell layer (GCL) (Figure
5A, left panel). Some of these cells were immunopositive
for PSA-NCAM, a marker for migrating neuroblasts (Fig-
ure 5A, right panel). These cells were then characterized by
injecting the mice with 5-bromo-2'-deoxyuridine (BrdU; 4
× 75 mg/kg) and sacrificing them 24 h later to assess the
number of progenitors that had incorporated BrdU.
Although no significant difference among genotypes was
seen in the total number of cells in the SGZ and GCL (Fig-
ure 5B), the total number of BrdU-labeled cells was mark-
edly higher in Tdo-/- than Tdo+/+ mice (Figure 5C and 5D),
suggesting enhanced proliferation and raising the concern
that there is different survival rate of new born cells
between wild-type and Tdo-/- mice. Confirming these BrdU
results, more than 87% of BrdU-positive cells were co-
labeled with Ki67, another marker for proliferating cells
(Figure 5C). Quantitatively, Ki67-positive proliferating
cells in the hippocampal SGZ and GCL were increased
1.9-fold, BrdU-positive cells 1.58-fold, and Ki67/BrdU
double-positive proliferating cells 1.64-fold in Tdo-/- over
Tdo+/+ mice (Figure 5C–5F).
To more precisely define the population of BrdU-positive
cells, Tdo-/- and Tdo+/+ sections were double-stained with
BrdU and nestin, a neural stem cell marker; the neural
progenitor (migrating neuroblast) markers DCX and PSA-
NCAM; and GFAP, on the basis of the recent identification
of GFAP-positive cells as neural progenitor cells in the
adult forebrain and hippocampus [24]. Results showed a
significant increase in BrdU-positive cells co-labeled with
nestin, GFAP, DCX, or PSA-NCAM in the SGZ of Tdo-/-
mice, indicating the promotion of both neural stem andMolecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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Modulation of brain Trp and serotonin metabolism by tdo disruption Figure 3
Modulation of brain Trp and serotonin metabolism by tdo disruption. (A-F) Trp and serotonin (5-HT) metabolites of 
the hippocampus (A-C) and midbrain (D-F) in 18- to 20-week-old Tdo+/+ (+/+) and Tdo-/- (-/-) mice. Trp (A, D), 5-HT (B, E), and 
5-HIAA (C, F) contents in the hippocampus (upper) and midbrain (middle) were determined using an HPLC-FD system (means 
± S.E.). *, p < 0.01. **, p < 0.0001. (G) tryptophan hydroxylase (tph2) mRNA levels and enzymatic activity in the adult midbrain of 
Tdo+/+ (+/+) and Tdo-/- (-/-) mice. (left) tph2 mRNA expression in the midbrain. TaqMan RT-PCR analyses were performed using 
total RNA extracted from the midbrain of 14- to 16-week-old mice. After normalization to gapdh, data were expressed as % 
fluorescent units relative to those in Tdo+/+ mice. Data represent means ± S.E. (right) Assay for TPH enzymatic activity. TPH 
enzyme activity was measured using midbrain homogenates obtained from 15-week-old mice of each genotype. Values repre-
sent means ± S.E. N.S., not significant.Molecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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Anxiety-related behavior tests of 13- to 15-week-old Tdo+/+ (+/+) and Tdo-/- (-/-) mice Figure 4
Anxiety-related behavior tests of 13- to 15-week-old Tdo+/+ (+/+) and Tdo-/- (-/-) mice. (A-C) Elevated plus maze 
tests. Duration in the open arms (A) and center zone (B), and total distance traveled (C) were scored for 5 min. Data repre-
sent the mean ± S.E. (D -F) Open field tests. The ratio between locomotion in the center and total locomotion (D), duration in 
the center zone (E), and total distance traveled (F) were scored for 30 min. Data represent the mean ± S.E. *, p < 0.05. **, p < 
0.01. N.S., not significant.Molecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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progenitor cell proliferation in the SGZ of these mice (Fig-
ure 5G and Table 1).
Neural progenitors of the SGZ mature locally into granule
neurons of the dentate gyrus (DG), sending axonal projec-
tions to the CA3 area and dendritic arbors into the molec-
ular layer of the hippocampus. To assess the fate of BrdU-
positive neural stem and progenitor cells, mice were sacri-
ficed 28 days after BrdU injection. A large increase in the
number of BrdU-positive cells was observed throughout
the GCL and outer DG regions in Tdo-/- mice (Figure 5H).
By degree of differentiation, co-labeling of these BrdU-
incorporated cells with TuJ1, an early neuronal marker,
and NeuN, a marker of differentiated neurons, showed a
1.6-fold and 2.4-fold increase in early versus differenti-
ated neurons, respectively (Figure 5I and Table 2). Inter-
estingly, these increases were greater than those observed
following anti-depressant injection [23], suggesting a
marked acceleration of de novo neurogenesis in Tdo-/- mice.
Increased proliferation of neural progenitors in the 
subventricular zone and marked reduction in size of the 
lateral ventricles in 13-week-old Tdo-/- mice
To clarify whether this acceleration of neurogenesis was
restricted to the hippocampus, we next examined neuro-
genesis in the subventricular zone (SVZ), the second
region showing adult neurogenesis in mammals. On H&E
staining of coronal sections, the lateral ventricles (LVs) of
13-week-old Tdo-/- mice brains were only one-third the
size of those of Tdo+/+ mice. In contrast, no difference was
seen in other ventricular regions, including the dorsal
third ventricle (D3V) and aqueduct (Aq) (Figure 6A and
6B). Given that the subventricular zone (SVZ) is situated
throughout the lateral wall of the LV and is one of only
two regions that participate in adult neurogenesis in
mammals, and that higher levels of either or both Trp and
5-HT may thus affect morphological changes via the accel-
eration of neurogenesis, we next assessed the modifica-
tion of neurogenesis in SVZ of Tdo-/- mice.
To explore this possibility, BrdU (4 × 75 mg/kg) was
injected into 13-week-old mice, which were then exam-
ined 24 h later. On TO-PRO-3 iodide (nuclear) staining,
markedly more cells were seen in the SVZ of Tdo-/- than
Tdo+/+ mice, particularly in the region surrounded by cor-
pus callous (CC), striatum (Str) and LV, (Figure 6Ca and
6Cb). Further, Tdo-/- mice also showed more BrdU-posi-
tive cells in this region (Figure 6Cc–f) than wild-type
mice. Immunostaining for nestin (red) or nestin plus
BrdU (green, overlay view) in Tdo-/- mice revealed notice-
Increase in neurogenesis in the subgranular zone (SGZ) following tdo deletion Figure 5 (see previous page)
Increase in neurogenesis in the subgranular zone (SGZ) following tdo deletion. (A) H&E staining of the dentate 
gyrus (DG) of paraffin-embedded coronal brain sections (5 μm) of 13-week-old Tdo+/+ and Tdo-/- mice. Center and right panels, 
higher magnification views. Right panels, PSA-NCAM-immunostaining. (B-I) Estimation of proliferating neural precursors and 
neurogenesis in the hippocampus of 13-week-old Tdo+/+ and Tdo-/- mice. (B) Total number of nuclei/section in the SGZ and 
granular cell layer (GCL) is shown as total cells. (C) BrdU/Ki67-double staining in the DG at 24 h after BrdU injection. (D-F) 
BrdU-, Ki67-, and double-labeled cells are indicated as a percentage of total cells. (G) Double-immunostaining of anti-BrdU and 
neural markers (Nestin, GFAP, PSA-NCAM, or DCX) in the SGZ of Tdo-/- mice at 24 h after BrdU injection. (H) BrdU-immu-
nostaining in the DG at 28 days after BrdU injection. Nuclei were stained with TO-PRO-3 (blue). (I) TuJ1 and NeuN were co-
labeled with anti-BrdU at 28 days after BrdU injection. Orthogonal images show three dimensional analyses of individual cells 
marked by intersecting lines in the x, y, and z axes. Bars: 100 μm (C, H) and 30 μm (G, I). Data represent means ± S.E. *, p < 
0.05 versus Tdo+/+ mice.
Table 1: Quantitative analysis of proliferating neural progenitors in SGZ 24 h after BrdU injection.
Nestin + GFAP + PSA-NCAM + DCX +
Tdo +/+ 2.78 ± 0.23 5.31 ± 0.49 4.20 ± 0.45 0.80 ± 0.08
Tdo -/- 2.38 ± 0.13 6.90 ± 0.26* 6.07 ± 0.48* 1.49 ± 0.13*
Nestin+/BrdU+ GFAP+/BrdU+ PSA+/BrdU+ DCX+/BrdU+
Tdo +/+ 0.58 ± 0.12 0.34 ± 0.06 0.42 ± 0.08 0.77 ± 0.12
Tdo -/- 1.15 ± 0.13* 0.47 ± 0.05* 0.93 ± 0.09* 1.27 ± 0.11*
Cells positive for neural progenitor markers, alone and in combination with BrdU, are indicated as a percentage of total cells. Cells were counted in 
>3 matched sections from the DG of each mouse (n = 3 for each genotype). These data represent means ± S.E. *, p < 0.05 versus Tdo+/+ mice 
(ANOVA, Scheffe's post-hoc test).Molecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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ably more nestin-positive neural stem cells in the SVZ, not
only on the Str but also on the CC side (Figure 6D), sug-
gesting marked neural stem cell proliferation in the SVZ.
With regard to neural progenitor (migrating neuroblast)
cells, immunostaining for DCX (red) and BrdU (green,
overlay view) revealed a perceptible increase in the
number of proliferating DCX-positive neural progenitor
cells in the SVZ of Tdo-/- mice (Figure 6E). Similar results
were obtained using PSA-NCAM as an additional marker
for neural progenitor cells (Figure 6F). Taken together,
these findings demonstrate that the loss of TDO induces
the proliferation of both neural progenitors and neural
stem cells in the SVZ, and hence might contribute, either
fully or partly, to a decrease in the size of the LV.
Accelerated adult neurogenesis in the GCL of the olfactory 
bulb in 13-week-old Tdo-/- mice
Adult-born cells in the SVZ migrate along the rostral
migratory stream to the olfactory bulb (OB) where they
differentiate into interneurons. To determine if the
number of newly generated neurons migrating to their
final destination in the OB was altered in Tdo-/- mice, BrdU
was administered to 9-week-old mice, which were sacri-
ficed 4 weeks later. Although Cresyl violet-stained brain
sections showed little difference between genotypes in the
appearance of the OB (see additional file 1, Figure S2A),
the estimated number of BrdU-positive cells in the GCL of
the OB was 1.6-fold higher in Tdo-/- than Tdo+/+ mice (see
additional file 1, Figure S2C and S2E, middle panels).
These mice also showed an increase in the number of
BrdU/PSA-NCAM double-positive proliferating neurob-
lasts, presumably derived from the SVZ (see additional file
1, Figure S2B and S2C, right panels); and a notable
increase in the number of BrdU-positive cells co-labeled
with NeuN in the GCL (see additional file 1, Figure S2D
and S2E, right panel). These findings indicate that the
enhanced proliferation of neural progenitors in the SVZ
increased the number of migrating neuroblasts and
enhanced adult neurogenesis in the GCL in the OB of 13-
week-old Tdo-/- mice. Total PSA-NCAM- and NeuN-posi-
tive cell numbers of olfactory bulb were not altered in Tdo-
/- mice in a similar manner with dentate gyrus, raising the
concern that there is different survival rate of new born
neural progenitors and neurons between wild type and
Tdo-/- mice.
Discussion
Using mice deficient for tdo, we provide the first evidence
that TDO, one of two initial and rate-limiting enzymes for
the kynurenine pathway of Trp metabolism, is directly
linked to systemic Trp metabolism, neurogenesis and anx-
iety-related behavior in vivo. These mice had markedly
increased plasma levels of Trp, 5-HIAA, ILA and IAA in the
presence of IDO, demonstrating that the accumulation of
Trp and acceleration of serotonergic and transamination
pathways are largely dependent on TDO (Figure 1 and 2).
Although other tryptophan metabolic enzymes, such as
kynurenine formamidase, may also play a role in the reg-
ulation of systemic Trp levels and several important neu-
ral functions [16,25-27], we propose that the greater
severity of biochemical changes in our Tdo-/- mice, partic-
ularly in systemic Trp levels, than in other animal models
indicates that TDO is the key regulatory enzyme in the
modulation of systemic Trp levels. In addition to Trp, 5-
HT and 5-HIAA levels were also elevated in the hippocam-
pus and midbrain of these mice. Taken together, these
findings demonstrate that TDO, which is expressed pre-
dominantly in the liver, plays an essential and dominant
role in the in vivo regulation of brain levels of 5-HT, even
in the presence of tryptophan hydroxylase-1 (in the
periphery) and tryptophan hydroxylase-2 (in the brain).
This finding contrasts with those of previous studies,
which have indicated the latter two enzymes as rate-limit-
ing for 5-HT synthesis [6,28].
In contrast to our findings for Trp, plasma levels of Kyn
and KYNA, which are downstream Trp metabolites gener-
ated by TDO (Figure 1), were sustained at physiological
levels despite the absence of TDO. This finding suggests
the presence of compensatory mechanisms to maintain
Kyn and KYNA levels in Tdo-/- mice; and given that IDO
mediates the same metabolic processes as TDO in various
tissues, it is the most likely candidate. On this basis, IDO
would be expected to decrease plasma and brain Trp levels
but increase its downstream metabolites Kyn and KYNA
[29]. Our assessment of both TDO and IDO enzyme activ-
ities from liver lysates, however, showed a loss in the con-
version of Trp to Kyn in Tdo-/- compared with Tdo+/+ mice
(Figure 1F), suggesting that the compensatory mecha-
nism(s) may function in extra-hepatic tissues and, in part,
play a role in decreasing Trp level and increasing Kyn
level. In addition, a modulatory mechanism(s) in Kyn
pathway may also play a role. Increasing Trp concentra-
tions in food decrease the enzymatic activity of quinoli-
nate phosphoribosyltransferase (QPRT), a downstream
metabolic enzyme of TDO [30]. Although the mechanism
remains unclear, our findings thus raise the possibility
that Trp metabolism downstream of Kyn and KYNA plays
Table 2: Quantitative analysis of adult neurogenesis in SGZ 28 
days after BrdU injection.
NeuN + TuJ1 + NeuN+/BrdU+ TuJ1+/BrdU+
Tdo +/+ 91.28 ± 1.30 2.75 ± 0.33 0.47 ± 0.12 0.64 ± 0.12
Tdo -/- 89.62 ± 0.87 5.16 ± 0.47* 1.14 ± 0.12* 1.00 ± 0.13*
Cells positive for neural markers, alone and in combination with 
BrdU, are indicated as a percentage of total cells. Cells were counted 
in >3 matched sections from the DG of each mouse (n = 3 for each 
genotype). These data represent means ± S.E. *, p < 0.05 versus Tdo+/
+ mice (ANOVA, Scheffe's post-hoc test).Molecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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a role in maintaining plasma Kyn and KYNA levels in Tdo-
/- mice.
We also used these Tdo-/- mice to evaluate the role of TDO
in anxiety-related behavior. Although the mechanism
remains to be elucidated, TDO deletion had clear anxio-
lytic effects, as revealed by two classical behavioral tests.
In agreement with our data, Yamasaki et al. reported
marked reduction of the level of tdo mRNA in the hippoc-
ampus of alpha-CaMKII deficient mice (alpha-CaMKII+/-)
that show anxiolytic phenotype [31]. Trp and its catabo-
lite 5-HT are thought to modulate mood control [4].
Given that the roles of 5-HT1A receptor and 5-HT trans-
porter during development in anxiety-related behavior
have been reported, respectively [32,33], it is postulated
that  Tdo-/-  mice show anxiolytic change due to 5-HT-
upregulation in the brain and subsequent modulation of
neural development. In addition, in the adult, given pos-
tulation that 5-HT/5-HT1A receptor-mediated neurogene-
sis is critically involved in the anxiolytic effects of anti-
depressant fluoxetine [23], one likely mechanism of this
is that the deletion of hepatic TDO modulates plasma Trp
and subsequently increases brain Trp and 5-HT, which in
turn accelerates neurogenesis in the hippocampus. It
should be noted that tdo  and its variants mRNAs are
expressed in various regions of developing and adult brain
[34], suggesting a possible role of locally expressed TDOs
in the brain for the specific regional modulation of the
brain and subsequent behavioral modulation. Moreover,
altered immunoreactivity against TDO has been reported
in patients with schizophrenia and depression [35]. In
addition, given findings of a correlation between Kyn lev-
els and the regulation of behavior in insects and of an
increase in plasma Kyn concentration in endogenous anx-
iety in humans, we cannot exclude the possibility that
anxiety-related behavior is also modulated by TDO-
induced changes in Kyn, and possibly in other
kynurenines as well [36,37]. If the contribution of altera-
tions in Kyn to anxiety-related behavior is indeed impor-
tant, then TDO would appear to be a key modulator of
this behavior under physiological conditions via the con-
trol of both 5-HT and Kyn. This possible role of TDO
stands in contrast to that of TPH, which has been consid-
ered a rate-limiting enzyme in the synthesis of 5-HT but
not of Kyn.
The role of stress and stress-induced glucocorticoids in
affecting mood and anxiety is well known. Administration
of glucocorticoids to rats results in elevations of the tryp-
tophan-metaboliting enzymes and TPH in vivo and that
administration of dexamethasone phosphate regulates
TDO activity in cells from control and adrenarectomized
mice, respectively [38,39]. In addition, glucocorticoids
regulate either or both the activity and mRNA levels of
TDO in rat liver [40] and isolated primary hepatocytes
[41,42]. Indeed, stresses such as forced running, immobi-
lization and exposure to cold increase rat liver TDO activ-
ity [43]. Taken together, our findings raise the possibility
that TDO may in part contribute to the modulation of
mood and anxiety-related behavior by stress and environ-
ment (see additional file 1, Hypothetical model in Figure
S3).
Conclusion
In summary, we provide the first evidence that TDO plays
an essential role in the homeostasis of systemic and brain
Trp metabolism, including the dominant regulation of
serotonergic pathway, under the physiological conditions.
TDO also play a role in the maintenance of brain mor-
phology via regulating adult neurogenesis in the hippoc-
ampus and subventricular zone. Furthermore, TDO
modulates anxiety-related behavior, indicating a role of
TDO in higher brain functions. Collectively, the present
findings in Tdo-/- mice indicate a direct molecular link
between tryptophan metabolism and mental status. Tdo-/-
mice will likely prove useful in clarifying the physiological
role of Trp metabolism in normal brain function and in
psychiatric disorders, and for development of new
approaches for therapeutic interventions of mental disor-
ders.
Reduction in LV size and increased neural progenitors proliferation in the SVZ of Tdo-/- mice Figure 6 (see previous page)
Reduction in LV size and increased neural progenitors proliferation in the SVZ of Tdo-/- mice. (A) Paraffin-embed-
ded coronal brain sections (5 μm) were stained with H&E, and the size of each ventricle was measured. The boxed area in the 
subventricular zone (SVZ) was used for studies in Figures 6C-F. Arrows illustrate the change in the size of the LV in Tdo-/- mice. 
(B) Quantitative size of each ventricle in both genotypes. Relative mean size in each ventricle of Tdo+/+ mice was defined as 
100%. Results are expressed as the means ± S.E. and tested for significance with ANOVA and Scheffe's post hoc test (p < 0.05). 
(C-F) Incorporation of BrdU in neural progenitors of SVZ of Tdo+/+ and Tdo-/- mice. Frozen coronal sections (20 μm) of the SVZ 
of the brain of 13-week-old mice were stained with TO-PRO-3 (nuclei, Ca and Cb), BrdU (Cc-f, Dc-f, E, and F), DCX (E), PSA-
NCAM (F), nestin (Da, Db, De and Df) (boxed area in Figure 6A) at 24 h after BrdU injection. Inset, a merged view at high 
magnification (Df) of BrdU (green) and nestin (red). Ctx, cortex; Str, striatum; Sep, septum; Hip, hippocampus; D3V, dorsal 3rd 
ventricle; Aq, Aqueduct; and CC, corpus callosum. Bars: 100 μm.Molecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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Methods
Experimental animals
Mice were housed in groups of 3–4 per cage in a room
with controlled light (12 h light/dark cycle; lights on at 9
A.M.), humidity, and temperature, and allowed ad libitum
access to food and water. Only males were used for the
analyses. The acquisition, care, housing, use, and disposi-
tion of the animals were in compliance with the institu-
tional laws and regulations of the Osaka University
Graduate School of Medicine. All efforts were made to
minimize animal discomfort and the number of animals
used.
Construction of the targeting vector
Genomic DNA clones of the tdo locus were obtained from
the 129/SvJ mouse-derived genomic library ([44]; the
kind gift of Dr. T. Morita, Osaka University) using rat tdo
cDNA [10] as a probe. Among the clones, a 12.5-kb tdo
genomic fragment containing exons 1 to 3 was used to
construct a tdo targeting vector, which was prepared by
replacing exons 1 and 2 of the tdo fragment containing the
translation initiation site with the PGK-neomycin (Neo)
cassette at HindIII-XbaI sites. Subsequently, the ApaI-EcoRI
9.0-kb fragment (left arm, 6.5-kb; right arm, 2.5-kb) was
excised and inserted into the MC1 promoter driven diph-
theria toxin (DT)-A cassette in order to connect the 5' end
of the insert to DT-A.
Disruption of the tdo locus
R1 embryonic stem (ES) cells (kindly provided by Dr. A.
Nagy, Mt. Sinai Hospital, Canada, via Dr. H. Kondo,
Osaka University, Japan) were electroporated with linear-
ized targeting vector DNA, and selected with G418. G418-
resistant ES clones harboring the desired homologous
recombinations were verified by Southern blot analysis as
previously described [44,45] after the genomic DNA was
digested with PvuII, using a probe specific for the intron
sequence between exons 3 and 4 of tdo (Figure 1B). ES
cells that underwent homologous recombination were
microinjected into(C57BL/6 × DBA/2) F1 (BDF1) blasto-
cytes. Male chimeras were crossed with C57BL/6 females
to generate germ-line heterozygous offspring, with trans-
mission of the targeted allele verified by Southern blot
analysis. After backcrossing with wild-type C57BL/6 mice
(SLC, Shizuoka, Japan) for 5 generations, homozygous tdo
mutants and wild-type animals were obtained by inter-
crossing heterozygotes. Genotyping of progeny was per-
formed by Southern blot analysis of tail-derived genomic
DNA.
RNA purification and quantitative real-time RT-PCR
Total RNA was purified from the livers of 15-week-old
wild-type (Tdo+/+), heterozygote (Tdo+/-), and homozygote
(Tdo-/-) mice using a TRIzol reagent (Invitrogen) according
to the manufacturer's instructions. Quantitative real-time
RT-PCR was carried out and mRNA levels were calculated
as described previously [46]. For amplification of mouse
tdo, tph2, and gapdh (the endogenous control), Universal
PCR master mix and FAM dye-labeled Taq-Man MGB
probes (Applied Biosystems) were used for mouse tdo
(exons 4 and 5, Mm00431715), tryptophan hydroxylase-2
(tph2, Mm00557717_m1) and for rodent gapdh (Taq-Man
rodent GAPDH control reagents VIC probe), and the
results expressed as the mean ± S.E.
Western blotting
Western blot analyses of liver lysates from 15-week-old
Tdo-/-,  Tdo+/-, and Tdo+/+ mice were done using anti-rat
TDO antiserum (1:2,000, [47]).
Assay for TDO activity
Liver homogenates were obtained from 10-week-old Tdo-/
-, Tdo+/-, and Tdo+/+ mice. Assays for hepatic TDO activity
were carried out using L-Trp as substrate as previously
described [48], with activity expressed as μmol of kynure-
nine formed per hour per gram of wet liver weight.
Measurement of amino acids in plasma and brain
Plasma was deproteinated with 5% sulfosalicylic acid, fil-
tered, and immediately analyzed for amino acid concen-
trations using automated ion-exchange chromatography
with lithium-based buffers on a high-speed amino acid
analyzer (L8500, Hitachi, Japan), or stored at -80°C.
Micro-dissected brain tissues were rapidly removed after
perfusion with ice-cold Hanks' balanced salt solution, and
extracted in a solution containing 0.5 M HClO4  and
0.025% EDTA. The tissue extracts were incubated on ice
and centrifuged at 12,000 g at 4°C. The collected superna-
tants were filtered and amino acid concentrations were
determined using the amino acid analyzer (Hitachi).
Quantitation of Trp metabolites
Plasma samples treated with trichloroacetic acid (TCA)
were prepared in the same way as that used for amino acid
analysis. Plasma levels of Trp metabolites (Trp, Kyn,
KYNA, ILA, IAA, 5-HT, and 5-HIAA) were determined
using HPLC-FD and HPLC-UV systems as previously
described [49]. The column used for HPLC was a reversed-
phase C18 (2.0 × 250 mm hypersil BDS column, Hewlett
Packard). The Agilent 1100 series fluorescence detector
utilized the following excitation and emission wave-
lengths: 287 nm/340 nm for Trp, ILA, IAA, 5-HT, and 5-
HIAA, and 254 nm/404 nm for KYNA. UV signals for Kyn
were monitored at 365 nm.
Brain samples were prepared in the same way as those for
amino acid analysis. Trp, 5-HT, and 5-HIAA were quanti-
fied as previously described [50], with fluorescence detec-
tor signals monitored at excitation and emission
wavelengths 287 nm/340 nm.Molecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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Assay for TPH activity
TPH activity in fresh brainstem from 15-week-old mice of
each genotype was determined as previously described
[51] with slight modifications. Assay mixture containing
0.3 mM L-Trp, 0.1 mM Fe(NH4)2(SO4)2, 1 mM 6-methyl-
tetrahydropterin (6-MPH4), 2 mM NSD1015 (a inhibitor
of the aromatic amino acid decarboxylase), 25 mM DTT,
2 mg/ml catalase, and 50 mM HEPES, pH 7.2 were reacted
at 30°C for 20 min with shaking in the dark. The reaction
was terminated by the addition of saturated TCA to a final
concentration of 10%, and the mixture was then chilled
on ice and centrifuged at 4°C. 5-hydroxytryptophan (5-
HTP) in the supernatant was separated on a μBondapak
ODS C18 HPLC column (Waters) with a mobile phase of
2.5% methanol in 40 mM sodium acetate buffer, pH 3.5.
A F1050 fluorescence detector (Hitachi) detected signals
at the excitation and emission wavelengths of 287 and
340 nm, respectively. TPH enzymatic activity was normal-
ized to total protein in the homogenate and expressed as
nmol 5-HTP/mg/h at 30°C.
Histological and immunohistochemical analyses
Mice were deeply anesthetized and transcardially perfused
with ice-cold phosphate-buffered saline (PBS; pH 7.4),
followed by 4% paraformaldehyde (PFA) in PBS. For
analyses of brain morphology and PSA-NCAM immunos-
taining, the brains were removed and embedded in paraf-
fin. Serial coronal sections (5 μm) were prepared,
deparaffinized and stained with hematoxylin and eosin
(H&E), or used for PSA-NCAM immunostaining. For
most immunostaining, brains were removed and cryopro-
tected in 10% and 20% sucrose in PBS at 4°C after per-
fusion with 4% PFA in PBS. Twenty-micrometer sections
were prepared using a cryostat, mounted on APS -coated
slides, and stored at -80°C. Primary antibodies were
applied to the sections for 24 or 48 h at 4°C after incuba-
tion with blocking buffer containing 10% goat or donkey
serum and 0.3% Triton X-100 in PBS. The following pri-
mary antibodies were used: Ki67 (DAKO), nestin (BD
Pharmingen), GFAP (Chemicon), DCX (Santa Cruz),
NeuN (Chemicon), βIII-tubulin (TuJ1; Covance
Research), and PSA-NCAM (AbCys S.A.).
After washing with PBS, either Alexa Fluor 488- or Alexa
Fluor 546-conjugated secondary antibody and the nuclear
counterstaining reagent TO-PRO-3 iodide (Molecular
Probes) in PBS were applied. Sections were then washed
with PBS, mounted in Crystal mount (Biomeda) and
observed under a LSM 510 PASCAL confocal microscope
(Zeiss).
Quantification of ventricular size
The size of each ventricle (lateral ventricle, between 1.1
and 0.86 mm rostral; dorsal 3rd ventricle, between 1.7
and 1.94 mm caudal; and aqueduct, 4.36 and 4.48 mm
caudal to the bregma, as per Franklin and Paxinos, [52])
was analyzed in six paraffin-embedded sections per ani-
mal (n = 4 per group) and quantified using WinRoof soft-
ware (Mitani Corp., Japan), with the average size of the
ventricles in Tdo+/+ mice defined as 100%. Results are
expressed as the mean ± S.E.
Administration of BrdU and staining
BrdU (5-bromo-2'-deoxyuridine) injections and subse-
quent analyses were performed [23] using a BrdU-specific
antibody (Oxford Laboratory). In brief, to assess dividing
progenitors, 13-week-old mice were administered BrdU
(4 × 75 mg/kg) by intraperitoneal injection at 2 h intervals
and sacrificed 24 h after the last injection. To determine
the fate of BrdU-labeled cells, 9-week-old mice were
administered BrdU (4 × 75 mg/kg) and sacrificed 28 days
after the last injection. Brain sections were prepared as
described above. For BrdU immunohistochemistry, sec-
tions were fixed in acetone, treated with 1 N HCl for 30
min at 60°C to denature DNA, and rinsed in PBS. Subse-
quent processes for immunolabeling with the BrdU anti-
body were identical to those described above.
Cell quantitation in the hippocampus
Hippocampal sections from 13-week-old Tdo+/+ and Tdo-/-
mice prepared 1 and 28 days after the injection of BrdU
were examined for the number of cells immunopositive
for NeuN, TuJ1, PSA-NCAM, DCX, nestin, GFAP, BrdU,
and/or Ki67 [23]. In these experiments, cells in the total
surface of the granular cell layer (GCL) or in the subgran-
ular zone (SGZ) in the dentate gyrus (DG) were counted
in one of at least five sections per animal (n > 3 per group)
between 1.7 and 2.06 mm caudal to the bregma, as per
Franklin and Paxinos [52]. The total number of nuclei/
slice in the SGZ and GCL was defined as total cell number.
The percentage of double-immunostained cells was
obtained by analyzing three-dimensional reconstructed
BrdU-positive nuclei in x-z and y-z orthogonal projections
for the presence of cell markers.
Behavioral assessment using the elevated plus maze test 
and open field test
All behavioral tests (elevated plus maze and open field
test) were conducted between 9:30 AM and 1:00 PM. All
experiments were monitored by an automated video cam-
era system and analyzed with Ethovision Ver. 2.3.19 soft-
ware (Noldus, Wageningen, Netherlands).
Elevated plus maze
Tdo+/+ and Tdo-/- mice (13 to 15 weeks old) were tested in
an elevated plus maze according to Lister et al. [53] with
slight modification. In brief, the plus maze consisted of
two open (30 × 6 cm) and two wall-enclosed arms (30 ×
6 × 15 cm) connected by a central platform (6 × 6 cm).
The apparatus was elevated 40 cm above the floor. TheMolecular Brain 2009, 2:8 http://www.molecularbrain.com/content/2/1/8
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mouse was placed in the central zone facing an open arm,
which the animal would usually enter first, and explora-
tory behavior during a 5 min test period was monitored.
Testing took place during the light phase under standard
light.
Open field test
Open field tests were conducted in 13- to 15-week-old
Tdo+/+ and Tdo-/- mice according to the method of Paylor
et al. [54]. Briefly, the open field consisted of four adjacent
activity chambers (40 × 40 × 40 cm) surrounded by walls,
with the field lit from above. Mice were released into the
center of the field and allowed to roam the open field for
30 min. Total distance moved, time spent and the dis-
tances moved in both the margins (≤10 cm of the walls)
and center zone of the field (>10 cm from walls) were
measured. The ratio of the distance moved in the center to
the total distance moved was calculated and used as a
measure of anxiety-related behavior.
Statistical Analysis
Statistical analysis was carried out using StatView software
version 5.0.1 (SAS Institute, Cary, NC). Student's t-test
was used for the amino acid analyses, while the other data
were analyzed by one-way factorial analysis of variance
(ANOVA). A post-hoc test was carried out for ANOVA p-
values less than 0.05. Statistical significance was deter-
mined using Scheffe's post-hoc test at p < 0.05. Statistical
results were indicated as a p-value by the post-hoc test.
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